Regular ArticleIn Vitro Inhibitory Effect of 1-Aminobenzotriazole on Drug Oxidations Catalyzed by Human Cytochrome P450 Enzymes: A Comparison with SKF-525A and Ketoconazole
References (29)
- et al.
1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague- Dawley rats
Fundam. Appl. Toxicol.
(1992) - et al.
Autocatalytic inactivation of cytochrome P-450 and chloroperoxidase by 1-aminobenzotriazole and other aryne precursors
Tetrahedron
(1984) - et al.
Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450
Jpn. J. Pharmacol.
(2000) - et al.
Diethylaminoethyl 2,2-diphenylvalerate HCl (SKF-525A)-In vivo and in vitro effects of metabolism by rat liver microsomes-formation of an oxygenated complex
Biochem. Pharmacol.
(1972) - et al.
Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b 5 in the expression system and the differences in the marker activities
J. Pharm. Sci.
(2002) Reactions and significance of cytochrome P-450 enzymes
J. Biol. Chem.
(1991)- et al.
Extrahepatic metabolism of drugs in humans
Clin. Pharmacokinet.
(1994) - et al.
Clinical importance of hepatic cytochrome P450 in drug metabolism
Drug Metab. Rev.
(1995) - et al.
Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole
Biochem. J.
(1981) - et al.
Inactivation of rabbit pulmonary cytochrome P-450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole
J. Pharmacol. Exp. Ther.
(1985)
N-Aralkylated derivatives of 1-aminobenzotriazole as isozyme-selective, mechanism-based inhibitors of guinea pig hepatic cytochrome P-450 dependent monooxygenase activity
Can. J. Physiol. Pharmacol.
Cytochrome P-450 3A4: Regulation and role in drug metabolism
Annu. Rev. Pharmacol. Toxicol.
Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent
Drug Metab. Dispos.
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Br. J. Clin. Pharmacol.
Cited by (103)
Alkylphenols disrupt estrogen homeostasis via diradical cross-coupling reactions: A novel pathway of endocrine disruption
2024, Environment InternationalNew in vitro screening system to detect drug-induced liver injury using a culture plate with low drug sorption and high oxygen permeability
2023, Drug Metabolism and PharmacokineticsBenoxacor is enantioselectively metabolized by microsomes and cytosol from the human liver
2023, Emerging ContaminantsBiotransformation of sulfamonomethoxine in a granular sludge system: Pathways and mechanisms
2023, ChemosphereCitation Excerpt :Our results agree with previous studies that AMO co-metabolized many organic pollutants during ammonium oxidation (Wang et al., 2020a; Yu et al., 2018). CYP450 enzymes, commonly existing in microbes and easily restrained by 1-ABT, have extensive catalytic substrate spectrum and degradation ability of xenobiotics (Emoto et al., 2003; Jia et al., 2018). 1-ABT, a nonspecific mechanism-based inhibitor of CYP450, was applied for an inhibition test.
Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?
2022, European Journal of Pharmaceutical SciencesNovel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: Characteristics of non-enzymatic and glutathione S-transferase-mediated reactions: Conjugation of antitumor-active C-2028 with glutathione
2021, Journal of Pharmaceutical AnalysisCitation Excerpt :This was accomplished by two methods: 1) heat inactivation – RCyt fraction was incubated at 65 °C for 15 min before adding to the incubation mixture and 2) introduction of EA (0.5 mM), as a potent reversible GST inhibitor [18], to the incubation mixture. Incubation experiments of C-2028 with RLMs were also performed in the presence of 1 mM 1-ABT, a non-specific CYP450 inhibitor [19], to establish whether GSH-mediated conjugation pathway requires the prior substrate bioactivation by CYP450 enzymes. CDNB was used as a GST standard substrate to determine enzyme activity in liver matrices.